Zinbryta : EPAR - Summary for the public (PDF/539.87 KB)
First published: 19/07/2016
Last updated: 02/05/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Biogen Idec Ltd
|Date of issue of marketing authorisation valid throughout the European Union||
27/03/2018 Zinbryta - EMEA/H/C/003862 - IB/0015
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Zinbryta is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis (RMS).
EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders02/03/2018
PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage27/10/2017